Obesity is having an excessive amount of body fat in relation to lean body mass that may impair health.
The primary cause is an energy imbalance between calories consumed and expended.
Treatment goals include to lose 5-10% of body weight or 0.5-1 kg (1-2 lb)/week for 6 months and regain of <3 kg in 2 years and sustained reduction of waist circumference of at least 4 cm.
Strategies are aiming for realistic goals and a multidisciplinary approach that is a combination of dietary change, physical activity and behavioral modification.
High sedentary time (ST) and low moderate-to-vigorous physical activity (MVPA) among nonobese young adults are associated with increased adiposity, reports a new study. However, these factors do not predict change in adiposity over time.
Overweight or obese patients taking lorcaserin as an appetite suppressant may have the added benefit of a reduced risk of incident diabetes, according to results of the CAMELLIA-TIMI 61* trial presented at EASD 2018.
Clinically severe obese individuals may be prone to nutritional deficiencies, with a large number having suboptimal vitamin D levels, according to a study from Singapore. The deficiencies may also differ by ethnicity.
Not only are probiotics healthy for the gut, they may also be good for the waistline. A recent study shows that supplementation with the probiotic Bifidobacterium animalis subsp. lactis CECT 8145 (Ba8145) improves anthropometric adiposity measures such as waist circumference, body mass index (BMI), and visceral fat area in abdominally obese individuals, particularly in women.
Individuals with asthma may have a tendency to develop obesity, with a higher risk observed among those with adult-onset asthma, according to findings of the European Community Respiratory Health Survey (ECRHS) presented at the recent international congress of the European Respiratory Society (ERS 2018).
It appears that undesirable eating behaviour (EB) traits play a part in mediating genetic susceptibility to obesity, according to a recent study, suggesting that EB traits can be targeted in obesity treatment and prevention.
The combination of maternal pregestational diabetes mellitus plus severe obesity is associated with a heightened risk of several psychiatric and mild neurodevelopmental disorders in offspring compared with either obesity or diabetes alone, a study suggests.
A postnatal lifestyle intervention programme (PAIGE) for overweight women with previous gestational diabetes mellitus (GDM) leads to significantly greater weight loss compared with usual care at 6 months, a recent study has shown.
Elevations in inflammatory protein levels in neonatal blood are associated with obesity among 2-year-old children born extremely premature, a study reports. This suggests that systemic inflammation contributes to the development of obesity.
Taisho Pharmaceutical launches Lusefi®, an oral anti-diabetic medication for type 2 diabetes mellitus (T2DM). The medication is expected to lower blood glucose and provide adequate glycaemic control, serving as a new alternative prescription for T2DM. Lusefi, with its active ingredient luseogliflozin hydrate, is available in the form of 2.5 mg and 5 mg tablets.
At a recent Abbott lunch symposium held in conjunction with the joint 12th International Diabetes FederationWestern Pacific Region Congress & 10th Asian Association for the Study of Diabetes Scientific Meeting in KualaLumpur, Professor Shashank R. Joshi extensively discussed the issue of diabetes in obesity and the role of nutritionalintervention in addressing this growing problem.
Dapagliflozin is able to delay renal disease progression among patients with type 2 diabetes, even in those with normal kidney function, according to a study presented at the recently concluded Kidney Week 2019 of the American Society of Nephrology (ASN 2019).
In pancreatic cancer patients undergoing chemotherapy, the presence of diabetes mellitus is associated with reduced survival and larger tumour, as well as with increased risk of death after treatment, according to a meta-analysis.